立体定向放疗治疗新生血管性年龄相关性黄斑变性:STAR试验第3年和第4年扩展随访结果
STAR试验是一项随机、双盲、假手术对照的设备试验,纳入411例慢性、经治的活动性新生血管性AMD患者,比较一次性16 Gy立体定向放疗(SRT)与假照射。第4年意向性分析显示SRT组平均注射次数减少3.2次(95%CI -5.7至-0.7),但视力较假照射组差8.3个字母(95%CI -12.7至-4.0),结论不再支持SRT用于治疗新生血管性AMD。
要点
- 第4年SRT组平均注射19.1次,假照射组21.6次,调整后减少3.2次(95%CI -5.7至-0.7)。
- 第3至4年两组注射次数相近(SRT 8.4次 vs 假照射8.3次),早期减少的注射优势未能持续。
- SRT组最终视力较假照射组差8.3个字母(95%CI -12.7至-4.0),不再支持SRT用于新生血管性AMD。
核心结论
- 尽管至第4年眼内治疗总体减少得以维持,但SRT治疗眼视力更差,实际上逆转了第2年主要结局分析的结论,不再支持使用SRT治疗新生血管性AMD。
研究设计与样本
- 随机、双盲、假手术对照的设备试验,涉及从标准护理中预先计划的召回,在英国30家NHS医院开展。
- 共411例年龄至少50岁、患有慢性、经治的活动性AMD的参与者,274例分配至SRT组,137例分配至假SRT组。
- 干预为一次性16 Gy SRT或假SRT,使用机器人控制的设备递送;两年每月研究访视后恢复常规护理,抗VEGF药物选择和给药间隔基于当地实践,但保持设盲,并在第3年和第4年研究访视时重复数据收集。
主要发现
- 第4年意向性治疗疗效分析纳入SRT组222例(81%)和假SRT组106例(77%)参与者。
- SRT组四年内平均接受19.1次(标准差10.9)注射,假SRT组为21.6次(11.3),调整后减少3.2次注射(95%CI -5.7至-0.7)。
- 第3年和第4年期间,SRT组平均累积注射8.4次,假SRT组为8.3次。
- SRT组最终视力变化较假照射组差8.3个字母(95%CI -12.7至-4.0)。
- 不良事件发生率两组相似,但阅读中心检测到的微血管异常在SRT治疗眼为126/218(58%),假SRT治疗眼为16/102(16%)。
临床怎么用
- 基于第4年扩展随访结果,不推荐使用立体定向放疗治疗新生血管性AMD。
- 在临床试验中纳入标准护理、设盲的扩展随访可提供有用的临床见解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the effects of stereotactic radiotherapy (SRT) for neovascular age related macular degeneration (AMD) beyond the two year primary outcome of the StereoTactic radiotherapy for wet Age-Related macular degeneration (STAR) trial. DESIGN: Randomised, double masked, sham controlled, device trial involving preplanned recall from standard care. SETTING: 30 NHS hospitals in the UK. PARTICIPANTS: 411 participants aged at least 50 years with chronic, pretreated, active AMD. INTERVENTION: Participants received one-off 16 Gray SRT or sham SRT delivered using a robotically controlled device. After two years of monthly study visits, participants reverted to routine care, with anti-VEGF drug selection and dosing intervals based on local practice, but with masking maintained, and repeat data collection at years 3 and 4 study visits. MAIN OUTCOME MEASURES: The main efficacy outcome at year 4 was the number of anti-VEGF injections, tested for superiority (fewer injections). The other main outcome was visual acuity, tested for non-inferiority (five letter margin). Safety outcomes included adverse events, serious adverse events, and microvascular abnormalities. The same analyses were undertaken at years 2, 3, and 4. A within trial costing analysis was undertaken for participants with four years' follow-up. RESULTS: Of 411 participants (204 (58%) women), 274 were allocated to SRT and 137 to sham SRT. The year 4 intention-to-treat efficacy analysis included 222 (81%) participants in the SRT group and 106 (77%) in the sham SRT group. The SRT group received a mean of 19.1 (standard deviation 10.9) injections over four years versus 21.6 (11.3) with sham SRT, an adjusted decrease of 3.2 injections (95% confidence interval (CI) of difference -5.7 to -0.7). During years 3 and 4, the SRT group received a mean cumulative 8.4 injections versus 8.3 injections in the sham SRT group. The final change in visual acuity in the SRT group was 8.3 letters worse than in the sham group (95% CI of difference -12.7 to -4.0). Adverse event rates were similar between groups, but reading centre-detected microvascular abnormalities occurred in 126/218 SRT treated eyes (58%) and 16/102 (16%) sham SRT treated eyes. CONCLUSION: Although the overall reduction in intravitreal therapy was maintained to year 4, the inferior vision in SRT treated eyes effectively reversed the conclusions of the year 2 primary outcome analysis and no longer supports the use of SRT to treat neovascular AMD. Including standard care, masked, extended follow-up within a clinical trial may provide useful clinical insight. TRIAL REGISTRATION: ClinicalTrials.gov NCT02243878.
引用
- Jackson TL, Desai R, Wafa HA, et al. Stereotactic radiotherapy for neovascular age related macular degeneration: year 3 and 4 extended follow up results of a randomised, double masked, sham controlled, device trial (STAR). BMJ. 2026. PMID: 42315290. doi:10.1136/bmj-2026-729694
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。